About Us

Innolyzer Labs, LLC

Innolyzer Labs

Innolyzer Labs LLC is a privately-held company specializing in the development and commercialization of innovative analytics for a broad array of industries.  Our mission is to provide high quality, accurate, fast and affordable solutions to our customers with one-of-a-kind, lab-on-a-chip (LOAC) analysis devices.

Advancing technology in some industries while easing compliance and improving safety in others, Innolyzer is pioneering solutions that have become the gold standard for measuring H2S in aqueous samples.

With its proprietary technology, innovative processes and comprehensive expertise of our executive team and advisors, Innolyzer Labs is uniquely positioned across multiple world-wide markets to pioneer new territories for LOAC devices like our S-INC1, furthering technology in some industries while easing compliance and improving safety in others.

In addition to our experienced, professional executive team, Innolyzer employs a world-class team of advisors committed to its success.

John Chidlow, PhD

Co-founder and CEO

John Chidlow, PhD is the co-founder and CEO of Innolyzer Labs. Dr. Chidlow received his B.A. degree in Biology at Baylor University (2001), an M.S. degree (2005) and Ph.D. (2010) from the Department of Molecular and Cellular Physiology at LSUHSC-Shreveport. He completed a postdoctoral fellowship in the Department of Pharmacology at Yale University School of Medicine (2012). His research focused on vascular biology examining the relationship between inflammation and angiogenesis and on examining lipid transport across endothelium. He received the Dean’s Award for excellence in graduate studies and a Ruth Kirschstien post-doctoral research award. He then worked as Operations Manager at Syn Maxx II, LLC where he was involved in business planning, sales, directing research and development efforts, and financial management. During this time, Dr. Chidlow also created and managed his own company, J. Chidlow Consulting, LLC. At Innolyzer Labs, Dr. Chidlow is developing breakthrough analytic devices for market, with initial focus on the analysis of the hydrogen sulfide content of liquids.

Kevin Pavlick, PhD

Co-founder and COO

Kevin P. Pavlick, Ph.D., Co-founder and Chief Operations Officer: Dr. Pavlick is a co-founder of Innolyzer Labs and is currently working with the company as its COO. Dr. Pavlick received a B.S. in Pre-Medicine from Northeast Louisiana University in 1992 and then a Ph.D. in Molecular Biology and Biochemistry from LSUHSC-Shreveport in 2000.  Dr. Pavlicks training continued in the laboratory of Matthew Grisham in the Department of Molecular and Cellular Physiology, a renowned leader in the field of free radical biology, as a National Research Service Award Fellow. After completion of his post-doc training, Dr. Pavlick joined Johnson & Johnson Pharmaceutical Research and Development, LLC. (Spring House, PA) in 2005.  As a drug discovery scientist in the department of Enterology and then Analgesics, Dr. Pavlick led projects for the development of novel therapeutics and participated on external innovations during his tenure.  In 2010, he left Johnson & Johnson and returned to Shreveport where he gained knowledge in management of warehousing and distribution of beverages. Since 2014 Dr. Pavlick has brought his expertise to the development and launch of the Innolyzer Labs innovative products.

Chris Kevil, PhD

Co-founder and CSO

Dr. Kevil is a co-founder of Innolyzer and is currently working with the company part-time as its CSO, providing expertise in redox biology and chemistry. Dr. Kevil’s lab has pioneered advanced analytical chemistry detection of H2S in complex biological specimens and design of detection devices and uses that provide the foundation for Innolyzer’s product, S-INC1. His research program is focused on the relationship between cardiovascular disease and gasotransmitters, such as hydrogen sulfide and nitric oxide. His seminal work has revealed detailed mechanistic relationships between angiogenesis and inflammation, making him an internationally recognized expert in cardiovascular pathology. He currently serves as Associate Editor for the international journal Nitric Oxide: Hydrogen Sulfide and Carbon Monoxide, as well as a member of numerous editorial boards, including Cardiovascular Research, American Journal of Physiology — Heart and Circulation, Free Radical Biology and Medicine, Redox Biology, and Inflammatory Bowel Diseases. Dr. Kevil has received numerous national research awards and honors for his work.

Advisory Board

Leland Weiss, Ph.D., Scientific Advisor

Dr. Weiss holds the position of Assistant Professor of Bioengineering in the Institute for Micromanufacturing at Louisiana Tech University, and is serving as a prototyping and manufacturing advisor on Innolyzer’s Scientific Advisory Board.

Christopher B. Pattillo, Ph.D., Scientific Advisor

Dr. Pattillo holds the position of Assistant Professor in the Department of Molecular and Cellular Physiology at LSUHSC-Shreveport. Dr. Pattillo received his B.S. in Biophysics at Centenary College of Louisiana in 2001. He then obtained a M.S. in Biomedical Engineering at the University of Tennessee Health Science Center in Memphis, and obtained his Ph.D. in Engineering from Temple University. His research, while pursuing his graduate degrees, was focused on the development of a nontoxic injectable vehicle to deliver drugs specifically to destroy tumor vasculature. During this time he also worked on a project to engineer a microfluidic chamber to study micro vessel characteristics on a microscope slide. Dr. Pattillo did a postdoctoral fellowship in the Department of Pathology at LSUHSC. During this time he was awarded an NIH fellowship to study redox (NO, H2S, etc.) directed physiological angiogenesis, and characterized a new research imaging modality for the detection of experimentally altered blood flow changes. In 2012, Dr. Pattillo joined the Department of Molecular and Cellular Physiology at LSUHSC to continue his work studying the influence of cellular redox status as a potential avenue to develop therapeutic strategies.

Michael D. Pluth, Ph.D., Scientific Advisor

Dr. Pluth holds the position of Assistant Professor in the Department of Chemistry and Biochemistry at the University of Oregon, and is serving as an H2S biochemistry and detection advisor on Innolyzer’s Scientific Advisory Board. During his doctoral studies at UC-Berkeley, he developed a strong background in physical organic chemistry. Dr. Pluth’s doctoral work focused on stabilizing and exploiting reactive substrates within hydrophobic host molecules. During his postdoctoral studies at MIT, Dr. Pluth gained expertise working with small molecule gasotransmitters, analytical techniques in chemical biology, and cell/tissue culture techniques. His research focused on investigating how nitric oxide (NO) reacts with biomimetic iron species, developing fluorescent probes for biological NO, and using the developed NO probes to investigate the biological roles of NO. Currently, his research focuses on the development of new, application-driven chemical tools for understanding the biological roles of H2S. Dr. Pluth’s research group has positioned itself at the forefront of developing and applying new technologies to intercept, report, and modulate biological H2S. He is the recipient of multiple undergraduate, graduate and postdoctoral awards, and holds several prestigious grants.

Interested in what S-INC1 can do for you?

Get a Quote